[144] QUEST DIAGNOSTICS INC SEC Filing

Rhea-AI Filing Summary

Quest Diagnostics (DGX) Form 144 filing shows an insider planned sale and recent dispositions. The notice reports an intended sale of 227 common shares through Fidelity Brokerage with an aggregate market value of $42,706 and an approximate sale date of 09/26/2025. The 227 shares were acquired under an option (granted 02/19/2018) and will be paid in cash. The filer also reported two recent sales in the prior three months: 28,288 shares on 09/23/2025 for $5,293,312.79 and 175 shares on 09/24/2025 for $32,729.03. The filer attests not to possess undisclosed material adverse information.

Positive

• Transparent disclosure of planned sale details including broker, share count, and aggregate market value
• Acquisition method disclosed (option granted 02/19/2018), clarifying provenance of shares
• Recent prior sales reported with gross proceeds, providing context for insider liquidity

Negative

• Large prior disposition of 28,288 shares generating $5,293,312.79 could be perceived as notable insider selling
• Clustered sales within a short period (09/23/2025–09/26/2025) may prompt investor questions about timing

Insights

Securities Analyst

TL;DR: Insider option exercise and small planned sale following a materially larger disposition days earlier; disclosure is routine but notable.

The filing documents an insider selling 227 shares via broker-dealer after exercising options originally granted in 2018. The stated aggregate value of the planned sale is $42,706.00. The filing also discloses two recent sales totaling 28,463 shares generating roughly $5.33 million in gross proceeds. For investors, these transactions are transparent insider liquidity events rather than company operational news; the scale of the 28,288-share sale is materially larger than the 227-share planned sale and could reflect personal liquidity needs or portfolio rebalancing.

Corporate Governance Expert

TL;DR: Multiple insider sales within days raise governance and signaling questions but do not by themselves indicate corporate impropriety.

The filer signed a Section 144 notice covering an option-originated grant and short-window dispositions. The prominence is the 28,288-share sale on 09/23/2025 with gross proceeds above $5.29 million, followed by smaller sales; such clustered insider selling merits monitoring for patterns but is permissible if properly disclosed and compliant with Rule 144 and any 10b5-1 plans. The attestation of no undisclosed material information is included in the form.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	227	42706.00	111823441	09/26/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/26/2025	Option Granted 02/19/2018	Issuer			227	09/26/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Michael Prevoznik 500 Plaza Drive Secaucus NJ 07094	Common	09/23/2025	28288	5293312.79
Michael Prevoznik 500 Plaza Drive Secaucus, NJ 07094	Common	09/24/2025	175	32729.03

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Quest Diagnostics (DGX) Form 144 disclose about the planned sale?

The filing states an intended sale of 227 common shares through Fidelity with an aggregate market value of $42,706.00 and an approximate sale date of 09/26/2025.

How were the 227 shares acquired according to the filing?

The 227 shares were acquired via an option granted on 02/19/2018 and the planned payment method is cash.

Did the filer sell other Quest Diagnostics shares recently?

Yes. The filer sold 28,288 shares on 09/23/2025 for $5,293,312.79 and 175 shares on 09/24/2025 for $32,729.03.

Which broker will handle the planned sale?

The sale is to be executed through Fidelity Brokerage Services LLC at the address listed in the filing.

Does the filer claim to have undisclosed material information?

The filer represents by signing the notice that they do not know any material adverse information about the issuer that has not been publicly disclosed.